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Abstract: We review evidence to support a model where the disease process underlying autism may 
begin when an in utero or early postnatal environmental, infectious, seizure, or autoimmune insult 
triggers an immune response that increases reactive oxygen species (ROS) production in the brain that 
leads to DNA damage (nuclear and mitochondrial) and metabolic enzyme blockade and that these 
inflammatory  and  oxidative  stressors  persist  beyond  early  development  (with  potential  further 
exacerbations), producing ongoing functional consequences.  In organs with a high metabolic demand 
such  as  the  central  nervous  system,  the  continued  use  of  mitochondria  with  damaged  DNA  and 
impaired  metabolic  enzyme  function  may  generate  additional  ROS  which  will  cause  persistent 
activation of the innate immune system leading to more ROS production. Such a mechanism would 
self-sustain and possibly progressively worsen. The mitochondrial dysfunction and altered redox signal 
transduction pathways found in autism would conspire to activate both astroglia and microglia.  These 
activated cells can then initiate a broad-spectrum proinflammatory gene response.  Beyond the direct 
effects of ROS on neuronal function, receptors on neurons that bind the inflammatory mediators may 
serve to inhibit neuronal signaling to protect them from excitotoxic damage during various pathologic 
insults (e.g., infection). In autism, over-zealous neuroinflammatory responses could not only influence 
neural  developmental  processes,  but  may  more  significantly  impair  neural  signaling  involved  in 
cognition in an ongoing fashion.  This model makes specific predictions in patients and experimental 
animal  models  and  suggests  a  number  of  targets  sites  of  intervention.  Our  model  of  potentially 
reversible pathophysiological mechanisms in autism motivates our hope that effective therapies may 
soon appear on the horizon. 
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INTRODUCTION 
 
  An emerging focus in autism research on metabolic 
and  tissue  properties  of  living  brains  marks  a  move 
beyond  methodologies  and  models  that  to  date  have 
predominantly  been  applied  to  determining  the  brain 
basis of autism. Approaches to the brain in autism have 
been conditioned by inferences drawn from a number of 
considerations: 1) the presence of a set of behaviors that 
are  strongly  associated  in  a  syndrome,  2)  high 
monozygotic concordance and recurrence rates and 3) 
physical  evidence  in  neuropathological  and  brain 
imaging  studies  of  neuroanatomical  abnormalities, 
some of which are consistent with prenatal onset. The 
inferences drawn from these considerations have until 
recently largely focused on the model of a genetically-
based disorder of prenatal pathogenesis where altered 
development  has  led  to  structural  abnormalities  that Am. J. Biochem. & Biotech., 4 (2): 167-176, 2008 
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underlie functional aberrations. These assumptions have 
driven  a  research  agenda  strongly  biased  towards 
seeking  mutations  in  developmental  genes  and 
identifying structural abnormalities in brain regions that 
might  plausibly  be  associated  with  identified 
neurocognitive impairments, as well as for mechanisms 
that might lead to neuroanatomical alterations occurring 
early in development. 
  However this research program has not delivered 
findings that clearly support these inferences.  No genes 
of strong effect have been identified other than possibly 
a small number of syndromic autism cases (e.g. Fragile 
X),  yet  even  in  those  cases  the  specific  modulatory 
mechanisms underlying the lack of full penetrance have 
not  been  elucidated
[1].  Additionally,  brain  changes  of 
various  types  have  been  documented  to  exist  during 
postnatal period, including increasing brain volume
[2,3], 
persistent  immune activation
[4] and diminution of cell 
size
[4], with the latter two continuing substantially into 
the lifespan.  With genes of strongest effect "causing" 
autism  in  less  than  half  of  individuals  carrying  such 
genes  and  with  the  recognition  of  postnatal 
pathophysiologies,  the  progress  of  neurobiology  is 
undermining the arguments for construing autism as a 
purely  prenatally  determined  brain  disorder.    In  fact, 
discourse on autism is increasingly including not only 
the  term  neurodevelopmental  but  also  the  term 
neurodegenerative in characterizing the disorder. 
  Yet  even  such  postnatal  changes  as  have  been 
documented  in  autism  are  not  of  the  character  or 
severity  that  would  be  expected  in  a  severe  and 
relentless  neurodegenerative  process.    Although  the 
steeply rapid pace of very early brain enlargement does 
not continue past the first year or two of postnatal life
[2] 
and  although  there  may  conceivably  be  mild  volume 
loss  into  the  middle  of  the  lifespan
[5],  major  volume 
loss,  massive cell death or brain atrophy is not seen.  
Furthermore, there is currently no evidence at all that 
these volume changes (increase or loss) are due to the 
process that is the basis  for autism. Neither have  we 
seen to date an appreciable shortening of the lifespan 
due to the disease process itself
[6]. Thus we cannot call 
upon mechanisms of frank tissue destruction to account 
for autism's functional deficits. 
  The notion of abnormal brain connectivity that is 
now being fleshed out in an expanding research domain 
poses  yet  another  challenge  to  the  assumptions  that 
have up until recently dominated autism brain research.  
This  notion,  discussed  as  early  as  the  1960s
[7]  and 
1980s
[8], has reemerged in the setting of technologies 
facilitating its measurement as the idea that covariance 
or  co-activation  between  brain  regions  in  autism  is 
altered or reduced in a widely distributed fashion
[9,10]. 
Placed alongside of documented brain enlargement and 
in particular of white matter enlargement, it is tempting 
to attribute altered connectivity to altered distribution of 
axons, with an increase in short-range but a decrease in 
long-range  connectivity  explaining  altered  processing 
patterns being documented by functional neuroimaging 
and electrophysiology.
[11,  12]  However, given that the 
anatomical enlargement does not persist into adulthood 
whereas  altered  functional  connectivity  has  been 
measured in adults, it bears reflection that this altered 
functional connectivity may not be based primarily in 
macroanatomical  alterations.    Moreover,  the  small 
amount of tissue-oriented imaging studies published to 
date that attempt to characterize the physical changes 
underlying autism have brought into question whether 
the  areas  documented  as  enlarged  have  more  axons, 
thicker  myelination  (oligodendroglial  hypertrophy), 
astroglial  hypertrophy,  microglial  hypertophy,  or 
simply  increased  or  altered  fluid  content
[13]. 
Furthermore,  specific  mechanisms  by  which  such 
structural  changes  might  directly  relate  to  altered 
function have not been established.  
  The  possibility  might  still  remain  that 
microanatomical architectural abnormalities may be the 
driving force underlying the autistic functional deficits. 
Abnormalities in receptors, interneurons, Purkinje cells, 
dendritic  arborization,  minicolumns  and  other 
microscopic  abnormalities  are  abundant  in  autism 
literature
[14,15]. Even here,  however, debate has arisen 
on a number of points.  First, interpretations of such 
abnormalities as being prenatal have been challenged 
by arguments proffering mechanisms by which at least 
some  of  these  changes  could  occur  due  to  postnatal 
phenomena.  For instance, minicolumnar abnormalities 
could arise early in gestation but they might also be a 
consequence of postnatal nitric oxide abnormalities
[16], 
while Purkinje cell dropout could result from postnatal 
excitotoxicity
[17].  Yet,  there  are  always  intrinsic 
problems  posed  by  working  with  human  postmortem 
material  and  repeatedly  throughout  history  such 
patterns  have been associated  with a  variety of other 
neurologic  conditions  including  for  example  infantile 
spasms.  Second, it has not been adequately assessed 
whether the microanatomical abnormalities documented 
to date are static architectural endpoints or whether they 
might be potentially dynamic conditions that are being 
modulated  by  chronic  features  of  autism,  such  as 
immunity  or  oxidative  stress,  but  that  might  rebound 
were  the  chronic  aggravating  stressors  to  abate.  
Regarding Purkinje cells, the recent findings that these 
cells stain with calbindin but not with Nissl has been 
interpreted  as  being  a  consequence  of  agonal  or 
postmortem  changes
[18],  but  it  has  not  been  excluded Am. J. Biochem. & Biotech., 4 (2): 167-176, 2008 
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that  the  problem  could  have  been  with  the  status  of 
these  cells  before  death  and  that  the  poor  uptake  of 
Nissl  stain  might  instead  reflect  an  ongoing  stress 
response  (e.g.,  chromatolysis,  a  depletion  of  somatic 
rough  endoplasmic  reticulum)  related  to  chronically 
diseased and weakened cells during life.  
  Substantial  clinical  observation  supports  the 
existence of considerable intra-individual variability in 
at  least  some  children  with  autism.    This  has  been 
poorly studied, presumably because the research agenda 
has been focused on autism as a condition that is stable 
across  the  life  course.    Research  attention  is  now 
starting  to  be  paid  to  those  children  whose  autism 
becomes less severe over time as well as to those who 
lose their autism diagnosis
[19,20]. Also being investigated 
are  intriguing  transient  changes  in  severity,  such  as 
fairly common reports that some children in the setting 
of high fever show improvements in eye contact and 
communication skills that then are lost when the fever 
subsides
[21-24]. These clinical observations and the latter 
ones  in  particular,  suggest  that  at  least  some 
components of autism  may in at least some cases be 
reversible and related to a neuromodulator state.  While 
these neuromodulators may act upon an altered macro-
or micro-anatomical substrate, it nevertheless remains 
the case that such relatively stable substrate alterations 
alone could not explain this kind of changeability. 
  Intra-individual  clinical  variability  adds  a  new 
dimension  to  the  problem  of  studying  gene-
environment interactions.  Emphasis to date has been 
upon vulnerable neurodevelopmental mechanisms, with 
xenobiotics,  infectious  agents  and  autoimmune 
processes and their immunologic consequences having 
an  impact  on  brain  development.  While  our  model 
includes intra-uterine maternal insults (Fig. 1), whether 
these  insults  persist  into  adulthood,  are  structural  or 
molecular  and  are  irreversible  or  reversible  remains 
open for debate. Many of the signaling molecules and 
other mechanisms by which environmental agents may 
affect neurodevelopment could also modulate function 
in  an  already  developed  brain.    Although  some 
postnatal development continues into early childhood, 
autistic  regression  of  the  infant  argues  in  favor  of  a 
functional model with potential reversibility. 
  While such potentially reversible mechanisms have 
not been the focus of autism research, enough is known 
about these cellular and molecular processes to at least 
sketch  out  a  plausible  research  program  oriented 
towards identifying modulators of neural function and 
plasticity  that  may  be  chronic  and  yet  under  certain 
circumstances  also  variable  in  their  severity  and 
conceivably also even treatable. 
 
 
Fig. 1:  An overview of the various classes of cellular, 
environmental,  and  genetic  factors  potentially 
leading to the behavioral defects in language, 
social behavior, and sensory processing 
 
Mechanisms: From the vantage point described above, 
evidence from the metabolic and molecular levels can 
be  reviewed  to  highlight  dimensions  of  chronic  and 
functional  as  well  as  developmental  and  structural 
features  pertinent  to  behavioral,  processing  and 
biological  phenotypic  characteristics  that  have  been 
measured as different from typical function in autism. 
  Within  the  set  of  interlocking  mitochondrial, 
inflammatory  and  molecular  mechanisms  that  have 
been  associated  with  autism,  there  appear  to  be  a 
number of phenomena that could readily associate with 
neuronal dysfunction rather than cell death. Particularly 
pertinent  is  the  interrelationship  of  mitochondrial 
dysfunction,  neuroinflammation  and  neuronal 
dysfunction  diagramed  in  our  model  (Fig.  1). 
Mitochondrial  dysfunction  has  been  reported  in  a 
significant  fraction  of  autistic  patients
[25-27].  Activated 
microglia,  also  documented  in  autism,
[28]  produce  an 
excess of reactive oxygen species and reactive nitrogen 
species,  including  superoxide,  nitric  oxide  and 
peroxynitrite
[29-32],  which  subsequently  can  lead  to 
mitochondrial  DNA  damage  or  protein  modifications 
that  cause  mitochondrial  dysfunction.    Impaired 
methionine  metabolism  has  also  been  described  in 
autism and a hyperaccumulation of homocysteine that 
can  be  associated  with  such  impairments  has  been 
shown  in  rat  cerebellar  granule  cells  to  lead  to 
mitochondrial swelling and cytochrome c release that 
occurs  in  a  calcium  concentration-independent 
manner
[33]. An earlier report implicated DNA damage 
caused  by  high  homocysteine  levels  in  activating 
mitochondrial  disruption  in  rat  hippocampal  cell Am. J. Biochem. & Biotech., 4 (2): 167-176, 2008 
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cultures following a sequence of DNA breakage, poly-
ADP-ribose  polymerase  (PARP)  activation,  caspase 
activation,  p53  activation  and  loss  of  mitochondrial 
membrane potential
[34]. DNA breakage associated with 
hyperhomocysteinemia may be due to subsequent DNA 
undermethylation  and  accordingly  uracil 
misincorporation
[35].  It  is  notable  that  these  processes 
were directly reversed by inhibiting PARP.  
  In  utero  infections  have  been  associated  with  a 
postnatal  risk  for  neuropsychiatric  symptomatology 
independent of the specific infectious agent
[36].
 Beyond 
this,  evidence  in  the  literature  suggests  that  in  the 
setting of maternal inflammation alone, the child may 
sustain long-standing mitochondrial DNA damage and 
depletion.  HIV  negative  children  born  to  untreated 
HIV+  mothers  displayed  major  mitochondrial  DNA 
damage (40% depletion) that persisted throughout the 
two  postnatal  years  during  which  observations  were 
made
[37]. While the incidence of autism in children born 
to HIV+ mothers has not been examined, the data do 
suggest that any inflammatory condition in the mother 
might conceivably promote severe mitochondrial (and 
possibly  nuclear)  DNA  damage  to  her  child.  The 
mechanism  of  this  effect  is  suspected  to  occur  as 
follows.  Maternally  infected  cells  would  promote  an 
increased  production  of  inflammatory  cytokines  that 
cross  the  placenta  and  then  increase  interleukin  1￿, 
interleukin 6, TNF-￿ and interferon-￿ among others, by 
fetal  cells
[38].  Mitochondrial  DNA  fragmentation  may 
then be induced by free radical production associated 
with  the  increase  in  these  cytokines,  especially 
interferon-￿. The impact of this damage on nuclear and 
mitochondrial  DNA  damage  in  the  neuron  could  be 
even  more  severe  due  to  the  high  neuronal  energy 
consumption rate and the lack of cell turnover. Due to 
the  positive  feed-back  loops  formed  in  such  a 
mechanism (Fig. 1), the disease state could self-sustain 
and persist well into later life. Such a model could have 
relevance to a variety of disease processes. 
  Genetic  and  molecular  changes  that  have  been 
described  in  autism  and  interpreted  developmentally 
may also have chronic and ongoing features some of 
which moreover may be modifiable. A polymorphism 
in the upstream region of the hepatocyte growth factor 
receptor  c-Met    that  has  been  identified  in  a  study 
involving  1231  autistic  children  plus  appropriate 
controls
[39] has the dual consequences of a deficiency in 
c-Met  protein  level  corresponding  to  reduced 
transcription rate and a downregulation of hepatocyte 
growth  factor  (HGF)  production  as  c-MET/HGF 
signaling  is  directly  related  to  HGF  expression  via  a 
positive feedback mechanism
[40,41]. It is thus noteworthy 
that HGF levels have also been shown to be lower in 
high functioning autistic adult males
[42]. This raises the 
question  of  whether  biological  activity  of  HGF 
contributes  to  autism  symptomatology  in  a  chronic 
fashion.    Interestingly,  studies  suggest  c-MET  might 
mediate reversal of the microgliosis and astrogliosis in 
post-ischemic repair as evidenced by anti-apoptosis and 
the prevention of glial scar formation
[43-45], while HGF 
deficiencies were connected to an increased oxidative 
stress response
[46]. This latter connection is mediated by 
a  mechanism  in  which  specificity  protein  1  (Sp1),  a 
transcription factor that initiates c-MET expression, is 
inhibited in the presence of ROS
[46,47]. Sp1 inhibition is 
caused by the expression of Early growth factor 1 (Egr-
1)  which  binds  the  transcription  factor  competitively 
with  the  c-MET  upstream  initiation  region.    Egr-1 
expression is stimulated by ROS as demonstrated via 
the addition of H2O2
[48] as well as methamphetamines 
which cause ROS and free radical accumulation in the 
brain
[49]. Furthermore, HGF and c-MET both appear to 
be  pertinent  beyond  the  brain,  since  HGF  reduces 
inflammation  in  other  tissues
[50,51]  and  can  potently 
suppress dendritic cell  functions
[52]. Thus deficiencies 
of both c-MET and HGF lead to conditions that would 
promote inflammation or oxidative stress which would 
indeed increase the frequency of DNA breakage. Thus, 
less  c-MET  could  mean  less  control  of  inflammation 
(i.e.,  more  chronic  inflammation),  more  ROS,  more 
caspase-mediated  damage  and  more  uracil 
misincorporation.  It is hence worth dwelling upon the 
ways that a deficiency in either HGF or c-MET could 
initiate  and  also  potentially  promote  a  sustained 
immune  response  across  the  life  course  to  sustain 
processes  that  are  consistent  with  chronic  features  of 
autism pathophysiology and could therefore potentially 
be an important contributor to the autism phenotype. 
 
Function:  How  might  these  persistent  metabolic  and 
molecular dysfunctions and deficiencies lead to neural 
systems  dysfunction?    The  persistent  activation  of 
innate  immunity  in  the  CNS  as  observed  in  autism 
could  cause  ongoing  impairments  of  neural  circuit 
function through numerous mechanisms independent of 
its  possible  effects  on  cortical  column  number  and 
pattern.  In  fact,  considering  the  large  number  of 
cytokines, chemokines and lipid metabolites  found to 
be  elevated  in  the  CSF  and  tissue  from  the  brain  of 
individuals  with  autism
[4],
  one  would  be  surprised  if 
these  did  not  cause  any  effect  on  circuit  function. 
Suppression of neural circuit function during an innate 
immune  response  may  have  developed  as  a  defense 
against  excitotoxic  cell  death  and  other  forms  of 
permanent  cell  (e.g.,  mitochondrial  or  nuclear  DNA 
damage)  and  circuit  damage.  These  neural  tissue Am. J. Biochem. & Biotech., 4 (2): 167-176, 2008 
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responses  would  also  be  designed  to  be  readily 
reversible, whether through simple down-regulation of 
inhibitory  transcripts  and  proteins  or  through 
reformation  of  temporarily  disconnected  synaptic 
contacts. 
  At  the  neural  circuit  level,  there  are  numerous 
molecular  mechanisms  whereby  innate  immune 
inflammation  might  impair  function  of  circuits  that 
need  not  rely  on  disturbances  of  neuronal  progenitor 
migration  or  axonal  arbor  development  (growth, 
targeting or pruning) and moreover such neural circuit 
level functional mechanisms deserve attention because 
of potentially reversible features. We present this model 
of reversible functional defects as an alternative view 
point to the dominant paradigm in autism research. As 
described in earlier paragraphs, consideration of such 
alternative  models  is  motivated  by  the  evidence  of 
reversibility, regression and ongoing CNS inflammation 
in  autism.  However,  we  must  point  out  that  this  is 
simply  an  alternative  view  point  and  developmental 
models  could  also  be  built  to  explain  the  behavioral 
features observed in autism research.  
  Innate  immune  inflammation  of  the  brain  causes 
severe disturbances of cognition.  Dementia, a deficit in 
learning and memory, develops in the context of innate 
immune inflammation of the CNS associated in human 
immunodeficiency  virus  (HIV)  encephalopathy.  This 
retroviral  infection  of  microglia  triggers  a  persistent 
innate  immune  inflammation  within  the  CNS 
characterized  by  a  mild-to-moderate  microglial  and 
astroglial hypertrophy without causing any evidence of 
cell death or damage.  Of note and by analogy to HIV 
encephalopathy, in autism, cell death is not observed 
and  cell  damage  is  subtle  and  the  brains 
macroscopically and microscopically for the most part 
look clinically normal with the exception of a mild-to-
moderate glial response
[15]. In HIV, careful examination 
of golgi-stained cortical neurons did eventually reveal a 
pattern of dendrite beading not seen in control brains
[53]. 
Dendritic  beading  has  been  observed  in  a  variety  of 
disorders including epilepsy and Alzhiemer’s disease, is 
triggered by NMDA receptor agonists and depends on 
sodium influx
[54-56]. In vitro studies of brain slices have 
been used to try to investigate the consequences of this 
morphologic  change  of  dendrites.  Treatment  of  brain 
slices with NMDA receptor agonists trigger the same 
pattern  of  dendritic  beading  and  the  response  is 
potentiated  by  the  inflammatory  mediator  lipid 
metabolite platelet-activating factor (PAF) that is found 
at high concentrations in the CSF of individuals with 
AIDS  encephalopathy
[57].  The  precise  signal 
transduction  pathway  and  intracellular  mediators 
remain largely  undefined. Functionally, the  formation 
of dendritic beads is associated with reduced synaptic 
long-term  potentiation  (LTP)  in  some  models  and 
chronic  synaptic  depression  in  others
[57,58].  Synaptic 
LTP  has  been  shown  to  be  critical  to  learning  and 
memory
[59,60].  Consequently,  one  might  speculate  that 
inflammatory  mediator-induced  dendritic  beading  and 
impaired LTP might prevent the synaptic encoding of 
language  and  social  response  patterns  as  a  potential 
basis  for  the  communication  deficits  seen  in  autism 
spectrum disorder. Dendritic beading has not yet been 
described in the autism neuropathology literature, but 
this same change was not initially recognized in HIV 
encephalopathy
[61]. 
  Innate  immune  inflammation  could  also  impair 
synaptic plasticity by impairing neuronal synchrony or 
promoting  aberrant  forms  of  neuronal  synchrony. 
Seminal  experiments  in  the  late  1990s  demonstrated 
that  presynaptic  and  postsynaptic  neurons  must  fire 
within  <100  ms  of  each  other  to  undergo  synaptic 
plasticity.  Furthermore,  reversing  the  order  of  firing 
inverted  the  plasticity  from  potentiating  to 
depotentiating
[62-65].
  Based  on  this  principle,  impaired 
synchronized firing of glutamatergic neurons could in 
principle  produce  aberrant  synaptic  plasticity. 
GABAergic  interneurons  are  interconnected  by 
electrical  gap  junctions  that  enable  them  to  form  an 
electrical syncitium which synchronizes their firing and 
the firing of their targets the glutamatergic pyramidal 
neurons
[66].  In  hippocampus,  minimal  stimulation 
evokes inhibitory synaptic currents which synchronize 
the firing of populations of CA1 pyramidal neurons
[67]. 
Chronic inflammation in the brain of an individual with 
autism might impair the ability of GABAergic networks 
to synchronize the firing of pyramidal neurons and to 
facilitate spike-timing dependent synaptic plasticity. A 
potential  basis  for  impaired  GABAergic  synaptic 
transmission  is  suggested  by  recent  studies  on  the 
impact  of  microglia  on  GABA  synapses  in  pain 
research.  In  studies  of  neurogenic  pain,  chronic 
inflammation due to microglial activation is generated 
by  traumatic  spinal  cord  injury.  Evidence  suggests 
activated  microglia  within  the  spinal  cord  release 
BDNF which collapses the anion gradient
[68]. BDNF via 
TrkB receptors down regulates the K+-Cl
- cotransporter 
KCC2 which impairs removal of intracellular (Cl
-)
[69]. 
Loss  of  this  chloride  gradient  would  eliminate  the 
hyperpolarizing  currents  evoked  by  GABAergic 
synapses.    The  spike  synchronization  described  by 
Cobb  et  al.
[67]  in  the  hippocampus  depends  on  the 
ability  of  the  GABAergic  synapse  to  transiently 
hyperpolarize the membrane of a large number of CA1 
pyramidal  neurons  causing  a  rebound  depolarization 
through  active  conductances  (e.g.,  T-type  Ca
2+ Am. J. Biochem. & Biotech., 4 (2): 167-176, 2008 
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channels
[70])  that  trigger  synchronous  firing  of  action 
potentials.  Synchronizing  the  firing  of  neurons  with 
collateral connections (e.g., layer II/III cortical or CA3 
hippocampal  pyramidal  neurons)  will  promote  spike-
timing-dependent  synaptic  plasticity.    The  failure  of 
such  mechanisms  could  be  used  to  explain  the 
"underconnectivity" that has been observed at the level 
of macroscopic circuitry level in autism
[9,10]. 
  Applying  the  same  concepts  of  spike-timing 
synaptic  plasticity,  one  should  note  that  by  simply 
inverting  the  order  of  synchronous  firing,  one  could 
also erase critical information previously encoded via 
synaptic potentiation. Aberrant patterns of synchronous 
circuit activity that occur in continuous spike-and-wave 
epilepsy  of  sleep  result  in  a  pattern  of  language  and 
sometimes  more  global  autistic  regression
[71,72].  We 
speculate  that  the  issues  go  beyond  the  potential 
problems for skill acquisition caused by the failure to 
synchronize  firing,  since  aberrant  synchronization  of 
firing  may  in  fact  depotentiate  synapses  in  these 
children  to  erase  the  synaptic  plasticity  events  that 
encode  learned  behaviors  associated  with  major 
developmental milestones. 
  These represent just two examples of mechanisms 
whereby  chronic  innate  immune  inflammation  could 
impair  synaptic  plasticity.  Some  of  the  cytokines, 
chemokines,  or  other  inflammatory  mediators  could 
also  regulate  the  central  neuromodulatory  systems 
(dopaminergic,  orexinergic,  histaminergic, 
serotonergic, noradrenergic, cholinergic) in the brain to 
not  only  influence  plasticity  but  also  produce  major 
disturbances  in  sleep-wake  cycle,  feeding,  or  social 
behavior
[73-75]  that  are  notable  parts  of  the  autism 
phenotype.   
  As  described  above,  there  is  ample  evidence  for 
defects  in  mitochondrial  function  in  autism.  In  some 
cases,  there  are  autism-associated  mutations  in  genes 
implicated  in  mitochondrial  metabolism  and  in  other 
cases  environmental  toxins  which  interfere  with  key 
enzymes involved in mitochondrial function. Are there 
neural  functions  that  could  bridge  directly  from 
neuronal  mitochondrial  dysfunction  to  behavioral 
deficits,  seizures,  or  sensory  pathologies  associated 
with autism independent of the inflammatory mediator 
effects?  One  potential  clue  is  the  observation  that 
collapsing  the  mitochondria  membrane  potential 
impairs the clearance of intracellular calcium in a large 
presynaptic terminus, the Calyx of Held
[76]. Although it 
is unclear whether mitochondrial defects cause similar 
effects in other major glutamatergic synapses, synaptic 
transmitter  release  was  decreased  by  50%  when 
mitochondrial function was impaired. We predict that 
any neuron that must sustain high firing rate such as a 
fast-spiking  GABAergic  interneuron  or  a 
thalamocortical  sensory  relay  neuron  (150-200  Hz, 
M.R.  Kasten  and  M.P.  Anderson,  in  preparation), 
transmission  may  be  particularly  prone  to  failure  in 
energy  deficiency  states.  Failures  of  GABAergic 
synaptic  transmission  could  unleash  seizures  and 
potentially cause regression in individuals as observed 
in epileptic encephalopathy.  Failure of thalamocortical 
neuron sensory transmission might impair sensory map 
formation in the cortex or impair the synaptic plasticity 
of  sensory-motor  circuits  needed  for  language 
acquisition. 
  Development of a mammalian model of the effects 
of  innate  immune  inflammation  on  neural  circuit 
physiology  and  plasticity  will  be  necessary  to  define 
which  signaling  molecules  are  the  major  players  and 
which  neural  circuit  mechanisms  are  impaired. 
Experimental  models  can  be  developed  to 
systematically  address  multiple  dimensions  of  an 
integrative  model  (Fig.  1)
[73].
  By  performing  these 
studies in the mouse, one can not only create autism-
associated gene mutations to model genetic components 
of the disease, but also  use  the power of conditional 
genetics (Cre/loxP and other technologies) to intervene 
on specific genes and neural circuitries (e.g., cortex vs. 
thalamus
[70])  to  define  precisely  where  inflammation 
acts  to  impair  function  and  behavior.  The  detailed 
mechanistic insights into autism pathophysiology that 
can be obtained through these approaches will almost 
certainly  inspire  novel  ideas  in  the  treatment  for  this 
life-long  neurological  condition  that  affects  so  many 
families today. 
 
CONCLUSION 
 
  The  above  considerations  suggest  a  number  of 
directions  for  model-building,  hypothesis  formulation 
and  research.    First,  the  shift  from  a  prenatal  and 
developmental perspective to a view that also includes 
ongoing  and  chronic  pathophysiology  raises  the 
question  of  the  functional  pertinence  of  mechanisms 
that  persist  past  the  periods  of  most  active  brain 
development.    Second,  the  shift  from  a  static  to  a 
dynamic  formulation  of  autism  allows  a  shift  in 
perspective on the source of intra-individual variability.  
Rather  than  considering  it  to  be  an  idiosyncratic 
rippling  over  an  unchanging  set  of  core  autistic 
features,  the  phenomenon  is  considered  potentially 
central to our understanding of autism pathophysiology 
providing  a  new  playing  field  for  exploring  its 
neurobiological foundations. And third, conceptions of 
potential treatment targets can be expanded to include 
modulation  of  mechanisms  that  may  be  genuinely Am. J. Biochem. & Biotech., 4 (2): 167-176, 2008 
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reversible  and  not  just  addressed  in  a  compensatory 
fashion. 
  Pursuit  of  these  novel  horizons  will  require  the 
coupling  of  a  number  of  levels  of  investigation  that 
hitherto  have  been  little  explored  in  autism  research, 
particularly  in  combination.    It  will  require  a 
hypothesis-driven  coupling  of  immune, 
metabolic/biochemical  and  neurophysiological 
investigations  and  it  will  also  require  in  vivo 
pathophysiological  investigations.    As  these 
methodologies  will  allow  the  exploration  of  potential 
avenues of plasticity in autism, implications for medical 
treatment  should  motivate  the  implementation  of  this 
research program. 
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